THE assessment process for AbbVie's oral hepatitis C treatment Viekira Pak (paritaprevir/ritonavir/ombitasvir and dasabuvir) has been summarised by the TGA in a newly published Australian Public Assessment Report (AusPAR).
The product is presented in a composite blister pack with 56 tabs of paritaprevir/ritonavir/ombitasvir and 56 dasabuvir tablets.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 17
